Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial - Horwitz, S; O'Connor, O A; Pro, B; ECHELON-2 Study Group (Lancet, 2019)
(10168):